Skip to content

Apneic Oxygénation by Nasal Canula During Infants Airway Management Study

Apneic Oxygénation by Nasal Canula During Infants Airway Management Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03967769
Acronym
Oxyeno
Enrollment
72
Registered
2019-05-30
Start date
2019-08-05
Completion date
2020-11-04
Last updated
2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Management, Infant Apnea, Surgical Procedure, Unspecified

Keywords

Apnoeic oxygenation, Airway management, Oxygen insufflation, Paediatric general anaesthesia

Brief summary

This is a randomized clinical trial investigating the utility of apneic oxygenation via high flow nasal cannulae during airway management for infants general anaesthesia. Three groups will be compared, a control group at 0 L/min, a 0,2L/Kg/min and a 1L/Kg/min group. The primary outcome will be the time (in seconds) between onset of apnea and one of theses end-points : desaturation (SPO2 \<95%) or Airway management completed.

Detailed description

Airway management can be a life saving therapy. One major complication that may occur during airway management is a lack of oxygen in the blood, especially in peadiatric population, due to anatomical and physiological considerations. If severe or prolonged, this lack of oxygen can result in permanent brain damage, damage to other vital organs or even death. Pre-oxygenation prior to induction of anaesthesia is standard practice to prevent desaturation and hypoxemia. Apnoeic oxygenation in adults is effective and prolongs the time to desaturation. Apneic oxygenation is a novel method of delivering oxygen to a patient despite a lack of active respiration (i.e. the patient is not breathing on their own and the investigators are not providing the patient an artificial breath). The simplest and least invasive method to provide apneic oxygenation is the application of oxygen through nasal cannula during airway management. The effectiveness of apnoeic oxygenation in the adult is well document, especially in bariatric population or ICU, however only few study are interesting about pediatric population. Recent studies suggest that high flow is similar to low flow oxygenotherapy. Therefore, the aim of this study was to investigate the effectiveness of apnoeic oxygenation during airway management in infants. This is a randomized clinical trial investigating the utility of apneic oxygenation via high flow nasal cannula during airway management for infant's general anesthesia. Three groups will be compared, a control group at 0 L/min, a 0,2L/Kg/min and a 1L/Kg/min group. The primary outcome will be the time (in seconds) between onset of apnea and one of these end-points : desaturation (SPO2 \<95%) or Airway management completed. All infants included will receive french actual standard of care concerning general anesthesia and peri-operative medicine.

Interventions

DEVICEHigh Flow nasal Cannula

Apnoeic Oxygenation by High Flow Nasal Cannulae

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

At each participating center, patients will be followed up for primary and secondary endpoints by members of the research staff who will be unaware of the trial group allocation. Information on whether the primary and secondary outcomes occur will be collected and entered into the electronic web-based case report form (eCRF) by trial or clinical trained personal (clinical research associate), blinded to the allocation group, under the supervision of the local principal investigator (PI) or designee who will also be unaware of the trial group allocation. Finally, the independent trial statistician and the members of the data monitoring and safety committee (DMSC) will also remain blinded for the allocation during analysis.

Intervention model description

Monocentric prospective, randomized, stratified, parallel-group clinical trial with concealed allocation to 3 groups of Apnoeic Oxygenation during Airway management for general anesthesia in elective surgery. All participants will receive French actual standard of care of surgery and anesthesia.

Eligibility

Sex/Gender
ALL
Age
No minimum to 24 Months
Healthy volunteers
No

Inclusion criteria

* Infants Between 0 (post-conceptionnal age \>41 weeks post Amenorrhea) and 24 months of life * Scheduled for elective surgery under general anesthesia * Need of orotracheal Intubation by direct laryngoscopy or Video-laryngoscopy

Exclusion criteria

* Emergency surgery * Crush Induction needed * High clinical risk of difficult airway management * Premature before 1 month of life

Design outcomes

Primary

MeasureTime frameDescription
Time between apnoea and issuesStart at the onset of ApnoeaTime, in seconds, between the onset of Apnoea (No EtCO2 on the capnogram) and one of these two Issues : * SpO2\< 95% * Airway Management Completed (Orotracheal intubation completed and 3 similar capnograms on the respirator)

Secondary

MeasureTime frameDescription
Time to SpO2 = 90% (in seconds)During Airway Management, after Apnoea OnsetTime between onset of apnoea and SpO2 = 90%, if it occurs, even if mask ventilation is started at Spo2 =95%
Numbers of Laryngoscopy attempts (n)During Airway managementNumbers of Laryngoscopy needed to secure Airways
Minimal SpO2 during the procedure (%)Between Onset of apnoea and airway management completedMinimal SpO2 recorded during the onset of apnoea and airway management completed
Area under SpO2 curveDuring Airway managementAUC of SpO2 recorded every 10 seconds
Respiratory Events (Incidence and type)During Airway managementIncidence of respiratory diseases during Airway management (Bronchospasm, Pneumothorax, Laryngospasm, Laryngeal Oedema)
Need to Face Mask Reventilating (Yes/No)During Airway management: Incidence of Face Mask Reventilating during Airway management, needed by Sp02 reach under 95%

Countries

France

Contacts

Primary ContactLise Laclautre
promo_interne_drci@chu-clermontferrand.fr+33 4 73 754963

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026